Amgen Canada Inc — licence 100048, currently licensed, last inspection rating C (2023-03-01).
No Canadian shortage report is currently matched to this DIN.
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02550970 | ADHEROZA | ACCORD HEALTHCARE INC | Powder For Solution | TRASTUZUMAB 150 MG | Approved |
| 02550989 | ADHEROZA | ACCORD HEALTHCARE INC | Powder For Solution; Kit | TRASTUZUMAB 420 MG | Approved |
| 02240692 | HERCEPTIN | HOFFMANN-LA ROCHE LIMITED | Powder For Solution | TRASTUZUMAB 440 MG | Marketed |
| 02480697 | HERCEPTIN SC | HOFFMANN-LA ROCHE LIMITED | Solution | TRASTUZUMAB 600 MG | Marketed |
| 02506211 | HERZUMA | CELLTRION INC. | Powder For Solution | TRASTUZUMAB 150 MG | Marketed |
| 02480794 | HERZUMA | CELLTRION INC. | Powder For Solution; Kit | TRASTUZUMAB 440 MG | Marketed |
| 02518244 | KANJINTI | AMGEN CANADA INC | Powder For Solution | TRASTUZUMAB 150 MG | Marketed |
| 02474425 | OGIVRI | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | Powder For Solution | TRASTUZUMAB 150 MG | Marketed |
| 02474433 | OGIVRI | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | Powder For Solution | TRASTUZUMAB 440 MG; WATER 20 ML | Marketed |
| 02524325 | ONTRUZANT | SAMSUNG BIOEPIS CO., LTD | Powder For Solution | TRASTUZUMAB 440 MG | Marketed |
| 02524317 | ONTRUZANT | SAMSUNG BIOEPIS CO., LTD | Powder For Solution | TRASTUZUMAB 150 MG | Marketed |
| 02512920 | PHESGO | HOFFMANN-LA ROCHE LIMITED | Solution | TRASTUZUMAB 60 MG; PERTUZUMAB 60 MG | Marketed |
| 02512912 | PHESGO | HOFFMANN-LA ROCHE LIMITED | Solution | TRASTUZUMAB 40 MG; PERTUZUMAB 80 MG | Marketed |
| 02483475 | TRAZIMERA | PFIZER CANADA ULC | Powder For Solution | TRASTUZUMAB 150 MG | Marketed |
| 02483467 | TRAZIMERA | PFIZER CANADA ULC | Powder For Solution | TRASTUZUMAB 440 MG | Marketed |